The Market Opportunity
We license validated, mechanism-annotated combination leads to pharma, so partners start from evidence, not a hunch. Market figures are drawn from third-party industry research and are provided for illustrative context.
$2.6B
Average cost of developing a new drug, reflecting the immense financial and scientific burden of the current discovery pipeline.
90%
Attrition rate of clinical-stage candidates, primarily due to the failure of single-target monotherapies against resistance.
4 yrs → 12–18 mo
target-to-preclinical
~30% CAGR
AI drug discovery
AI Market Growth
AI in drug discovery is a fast-growing market, valued at roughly $3-7 billion in 2025 and projected to grow at a ~24-30% CAGR, reaching tens of billions by the mid-2030s. We are positioned at the intersection of discovery and validation, leveraging generative AI to map and compress a 400-million-point search space into high-confidence, synergistic leads.
Market Opportunity
Our lead internal program demonstrates the platform's power by targeting the $13B advanced prostate cancer market, mapping mechanistically guided drug combinations to break through complex, reprogrammed resistance landscapes.